Publicly-traded company Acceleron Pharma Inc. (NASDAQ:XLRN) had a closing price of $40.27 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $58.67, this means that the stock is underpriced by 31.36%. In the past 52 weeks the company’s stock price has moved within the range of $37.01 to $59.08.
This particular stock’s 5-day moving average is 45.22, its 20-day moving average is 42.89 and its 100-day moving average is 42.75. Acceleron Pharma Inc. (XLRN) currently has 51.18M shares outstanding, which means that its market capitalization is $2.06B.
The Details: Acceleron Pharma Inc. (XLRN) Financial Health
Return on Assets is a number, expressed as a percentage that tells us how well a publicly-traded company is using its current assets to generate revenue. The higher the percentage, the better a company is using its assets to turn a profit. At the moment, Acceleron Pharma Inc. Return on Assets is -27.10%.
What Does Wall Street Say about Company?
When choosing stocks, many investors search for what Wall Street professionals think about the company first – like what the average rating is. At the moment, the average analyst rating for XLRN is Overweight. Out of 13 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 4 rated it hold, and 9 rated it a Buy.
Understanding Profitability at Acceleron Pharma Inc. (XLRN)
Taking a look at a public company’s Earnings per Share (EPS) is a good way of evaluating its profitability. In the most recent financial results released by Acceleron Pharma Inc., for the quarter ending on 09/2019, the company posted EPS of -0.81. The average estimate of Wall Street analysts had projected -0.68.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.82, compared to -0.63 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 10 analysts is 4.44M – compared to 3.26M posted in the year-ago period.